Director of Chemical and Pharmaceutical Sciences
Dr. Josh Bloom earned a Ph.D. in organic chemistry from the University of Virginia, followed by postdoctoral training at the University of Pennsylvania.
He worked for more than two decades as a research chemist for Lederle Laboratories, which was acquired by Wyeth in 1994, which itself was acquired by Pfizer in 2009.
During this time he worked in a number of therapeutic areas, including diabetes and obesity, antimicrobial agents, HIV/AIDS, hepatitis C, and oncology. His group discovered the novel antibiotic TygacilÂ®, which was approved by the FDA for use against resistant bacterial infections in 2005.
He is the author of 25 patents, and 35 academic papers, including a chapter on new therapies for hepatitis C in Burger s Medicinal Chemistry, Drug Discovery and Development, 7th Edition (Wiley, 2010), and has given numerous public lectures on how the pharmaceutical industry really works.
Dr. Bloom joined the American Council on Science and Health in 2010 as ACSH s Director of Chemical and Pharmaceutical Sciences, and has written more than 20 op-eds, which have appeared in major publications, including The Wall Street Journal, Forbes, The New York Post, National Review Online and Medical Progress Today. Dr. Bloom is a regular contributor to Science 2.0, where he writes on topics related to the pharmaceutical industry, medicine and junk science.